On August 6, Boston Scientific rose 3.53% in regular trading, trading at approximately $49.16 per share, with turnover of $33.86 million. The stock rebounded after falling 3.03% in the prior session amid ongoing pressure from a full-year guidance cut and multiple target price reductions.

On the news front, the bounce was supported by the fact that despite significant target price cuts, the majority of covering analysts maintained buy ratings. Deutsche Bank lowered its target from $75 to $60, UBS from $74 to $67, and RBC from $85 to $70, all retaining buy or outperform recommendations. UBS highlighted underappreciated growth drivers including coronary intravascular lithotripsy and renal denervation products expected in 2027-2028, representing a combined $2.5 billion addressable market, along with the Empower leadless pacemaker launch in 2027. UBS noted that current share pricing implies sales declines through 2029, which it views as overly pessimistic given the company's pipeline beyond its challenged Watchman and electrophysiology franchises.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)